Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases
Cabaletta Bio presented new Phase 1/2 data on rese-cel at ACR Convergence 2026 showing durable, immunomodulator-free responses across autoimmune diseases. All 6 dermatomyositis patients maintained moderate-to-major TIS responses through one year, all 5 biopsied lupus nephritis patients achieved DORIS remission, and 71% of systemic sclerosis patients hit rCRISS-50 at one year with 9% mean FVC improvement in lung-disease patients. Across 71 patients, 94% had no or Grade 1 cytokine release syndrome and no IEC-HS was reported, reinforcing the benefit-risk profile.
Key figures
- Drug Name
- resecabtagene autoleucel (rese-cel)
- Phase Of Trial
- Phase 1/2
- No icans
- 96% (68/71)
- Patients dosed
- 71
- Dm asys topline
- 2H 2027
- Grade 1 or no crs
- 94% (67/71)
- Ilc fvc improvement
- 9% mean at one year
- Blas submission timing
- Q1 2028 (myositis)
- Lupus nephritis DORIS remission
- 100% (5/5)
- Dermatomyositis TIS response 1yr
- 100% (6/6)
- Systemic sclerosis r CRISS 50 1yr
- 71% (5/7)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.